Related Experiment Video
Updated: Dec 20, 2025
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
The world is waiting, use sequential analysis and get us the evidence-based treatment we need for COVID-19
Adel El Taguri1,2, Aisha Nasef3,4
1National Center for Accreditation of Health Establishments- , Tripoli-Libya, Libya.
Abstract:
In spite of the relatively high morbidity and mortality, there is no approved medication yet for COVID-19. There are more than 200 ongoing trials on different drugs or vaccines, but new medications may take until 2021 to develop. Defining the optimal number of patients to be included in a study is a considerable challenge in these interventional researches. Ethical considerations prompt researchers to minimize the number of patients included in a trial. This gains particular importance when the disease is rare or lethal which is particularly so in the case of COVID-19. It is of paramount importance to explore some of the available tools that could help accelerate the adoption of any or some of the many proposed modalities for the treatment of diseases. These tools should be effective, yet efficient, for rapid testing of such treatments. Sequential analysis has not been frequently used in many clinical trials where it should have been used. None of the authors in published literature, as far as we know, used sequential analysis techniques to test potential drugs for COVID-19. In addition to its usefulness when the results of new forms of treatment are quickly needed, other important benefit of sequential analysis includes the ability to reach a similar conclusion about the utility of a new drug without unduly exposing more patients to the side effect of the old drug, in particularly, for the treatment of a rare disease.
Insights
Sequential analysis offers an efficient method for accelerating the testing of new COVID-19 treatments. This approach can yield conclusions faster and reduce patient exposure to potentially harmful drugs.
Area of Science:
- Clinical Research Methodology
- Infectious Diseases
- Pharmacology
Background:
- Despite high morbidity and mortality, no approved medications for COVID-19 exist.
- Over 200 trials are underway, but new drug development may extend into 2021.
- Determining optimal patient numbers in clinical trials presents a significant ethical and logistical challenge, especially for lethal diseases like COVID-19.
Purpose of the Study:
- To explore tools that accelerate the testing and adoption of potential COVID-19 treatments.
- To highlight the underutilization of sequential analysis in clinical trials.
- To advocate for the use of sequential analysis in evaluating new COVID-19 therapies.
Main Methods:
- The study discusses the principles and benefits of sequential analysis as a statistical tool.
- It reviews the current landscape of COVID-19 drug development and clinical trials.
- It posits sequential analysis as a method to optimize trial efficiency and patient safety.
Main Results:
- Sequential analysis allows for early stopping of trials once a conclusion is reached, saving time and resources.
- It can reduce the number of patients exposed to ineffective or harmful treatments.
- This method is particularly advantageous for rare or severe diseases where rapid treatment is critical.
Conclusions:
- Sequential analysis is an underutilized yet highly effective tool for accelerating the evaluation of new treatments for diseases like COVID-19.
- Implementing sequential analysis can lead to quicker therapeutic decisions, benefiting both patients and public health.
- Further adoption of sequential analysis in clinical trials is recommended to enhance research efficiency and ethical considerations.
Related Concept Videos
01:18Steps in Outbreak Investigation
01:05Single Nucleotide Polymorphisms-SNPs
01:13Controls in Experiments
01:25Statistical Methods for Analyzing Epidemiological Data